ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
NEW YORK, Nov. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
0,824$
2,98%
Echtzeit-Aktienkurs aTyr Pharma
Bid:
Ask:
Nachrichten zur aTyr Pharma Aktie
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action Lawsuits
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in aTyr Pharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATYR
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been…
Bragar Eagel & Squire, P.C. Reminds Investors of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights in Filed Class Action Lawsuits
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law…
aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman
SAN FRANCISCO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- A federal class-action lawsuit has been filed against aTyr Pharma,…
ATYR Investor Notice: Robbins LLP Reminds Investors of the Securities Fraud Class Action Against aTyr Pharma, Inc.
Robbins LLP is Investigating Allegations that aTyr Pharma, Inc. (ATYR) Mislead Investors Regarding the Efficacy of its Drug Candidate…
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After EFZO-FIT Study Failure Drives Shares 80% Lower -- Hagens Berman
ATYR Investors with Losses Encouraged to Contact Hagens Berman ATYR Investors with Losses Encouraged to Contact Hagens Berman…
aTyr Pharma: Zwischen Blockbuster-Potenzial und dem Damoklesschwert der Phase-3-Ergebnisse
Die zulassungsrelevante Phase-3-Studie zu Efzofitimod bei pulmonaler Sarkoidose ist ein wichtiger Katalysator. Topline-Daten werden im 3. Quartal 2025 erwartet.…
aTyr Pharma (ATYR): Nach Zwischendaten für eine laufende Studie sehen zwei Experten Potenzial für eine Kursvervielfachung!
aTyr Pharma (ATYR) hat am 04. Juni positive Ergebnisse einer Zwischenanalyse der laufenden Phase?2?Studie EFZO?CONNECT™ vorgestellt, in der der Wirkstoff…
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating
…
aTyr Pharma Inc. (ATYR): H.C. Wainwright sieht 775 % Kurspotenzial - Behandlung von entzündlichen Lungenerkrankungen wird an Bedeutung gewinnen
aTyr Pharma Inc. (ATYR) ist ein Biotechnologiekonzern, welcher evolutionäre Intelligenz nutzt, um die Biologie der tRNA-Synthetasen in neuartige Therapien gegen…
aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript
…
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
…
aTyr Pharma to Participate in September Investor Conferences
aTyr Pharma to Participate in September Investor Conferences…